Aggressive Medical Management for ICAD: A Comparison to the SAMMPRIS Trial (P1.174)

Conclusions:In a single center observational cohort study, we found that AMM in symptomatic ICAD yielded higher rates of recurrent stroke at 30 days when compared to the SAMMPRIS trial. This indicates that it may be more difficult to replicate the AMM and lifestyle modifications that were implemented in the SAMMPRIS trial and warrants further investigation.Disclosure: Dr. Sangha has nothing to disclose. Dr. Ansari has nothing to disclose. Dr. Bernstein has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., and Pfizer Inc. as a speaker/advisory board member. Dr. Corado has nothing to disclose. Dr. Curran has nothing to disclose. Dr. Ruff has nothing to disclose. Dr. Prabhakaran has received personal compensation for activities with the American Heart Association.
Source: Neurology - Category: Neurology Authors: Tags: Cerebrovascular Disease: Risk Factors and Prevention Source Type: research